These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10919031)

  • 1. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure.
    Eggermont AM; van IJken MG; van Etten B; van der Sijp JR; ten Hagen TL; Wiggers T; Oudkerk M; de Boeck G; de Bruijn EA
    Hepatogastroenterology; 2000; 47(33):776-81. PubMed ID: 10919031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study.
    van Etten B; Brunstein F; van IJken MG; Marinelli AW; Verhoef C; van der Sijp JR; Guetens G; de Boeck G; de Bruijn EA; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2004 Jun; 11(6):598-605. PubMed ID: 15172933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases.
    van Etten B; de Wilt JH; Brunstein F; Eggermont AM; Verhoef C
    Eur J Surg Oncol; 2009 May; 35(5):539-45. PubMed ID: 18760560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bio-chemotherapeutic strategies and the (dis) utility of hypoxic perfusion of liver, abdomen and pelvis using balloon catheter techniques.
    van Ijken MG; van Etten B; Brunstein F; ten Hagen TL; Guetens G; de Wilt JH; de Bruijn EA; Eggermont AM
    Eur J Surg Oncol; 2005 Oct; 31(8):807-16. PubMed ID: 15951150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives.
    Eggermont AM
    Anticancer Res; 1998; 18(5D):3899-905. PubMed ID: 9854502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs.
    van Ijken MG; de Bruijn EA; de Boeck G; ten Hagen TL; van der Sijp JR; Eggermont AM
    Ann Surg; 1998 Dec; 228(6):763-70. PubMed ID: 9860475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors.
    Nakamoto T; Inagawa H; Takagi K; Soma G
    Anticancer Res; 2000; 20(6A):4087-96. PubMed ID: 11131677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver.
    Rothbarth J; Pijl ME; Vahrmeijer AL; Hartgrink HH; Tijl FG; Kuppen PJ; Tollenaar RA; van de Velde CJ
    Br J Surg; 2003 Nov; 90(11):1391-7. PubMed ID: 14598420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
    Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC
    Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy.
    Alexander HR; Libutti SK; Bartlett DL; Pingpank JF; Kranda K; Helsabeck C; Beresnev T
    Cancer; 2002 Aug; 95(4):730-6. PubMed ID: 12209715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
    Grünhagen DJ; de Wilt JH; Verhoef C; van Geel AN; Eggermont AM
    Eur J Surg Oncol; 2005 Oct; 31(8):912-6. PubMed ID: 16098709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation.
    van Iersel LB; Verlaan MR; Vahrmeijer AL; van Persijn van Meerten EL; Tijl FG; Sparidans RW; Gelderblom H; Kuppen PJ; Tollenaar RA; van de Velde CJ
    Eur J Surg Oncol; 2007 Sep; 33(7):874-81. PubMed ID: 17400422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: a phase I-II trial.
    van Ijken MG; van Etten B; Guetens G; de Bruijn EA; Ten Hagen TL; Wiggers T; Eggermont AM
    Eur J Surg Oncol; 2005 Oct; 31(8):897-904. PubMed ID: 16084053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion.
    Verhoef C; de Wilt JH; Brunstein F; Marinelli AW; van Etten B; Vermaas M; Guetens G; de Boeck G; de Bruijn EA; Eggermont AM
    Ann Surg Oncol; 2008 May; 15(5):1367-74. PubMed ID: 18239976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.
    Vahrmeijer AL; van Dierendonck JH; Keizer HJ; Beijnen JH; Tollenaar RA; Pijl ME; Marinelli A; Kuppen PJ; van Bockel JH; Mulder GJ; van de Velde CJ
    Br J Cancer; 2000 May; 82(9):1539-46. PubMed ID: 10789721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated hepatic perfusion for liver metastases of malignant melanoma.
    Rizell M; Mattson J; Cahlin C; Hafström L; Lindner P; Olausson M
    Melanoma Res; 2008 Apr; 18(2):120-6. PubMed ID: 18337648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
    Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.